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Introduction: Pulmonary involvement represents a major cause of death of systemic sclerosis (SSc) patients. Recent
data suggest that tyrosine kinase inhibitors, such as imatinib, may be a therapeutic option for SSc patients.
However, preliminary published clinical trials were inconclusive about imatinib efficacy and showed side effects. The
purpose of this study was to verify efficacy and tolerability of low-dose imatinib on interstitial lung disease in a
cohort of SSc patients unresponsive to cyclophosphamide therapy.
Methods: Thirty consecutive SSc patients with active pulmonary involvement, unresponsive to cyclophosphamide,
were treated with imatinib 200 mg/day for 6 months followed by a 6-month follow-up. A “good response” was
defined as an increase of forced vital capacity (FVC) by more of 15% and/or increase of diffusing capacity of carbon
monoxide (DLCO) >15% and PaO2 > 90% of initial value and high-resolution computed tomography (HRCT)-scan
pattern unchanged or improved.
Results: Twenty-six patients completed the study. Three patients died and one patient was lost to follow-up. Four
patients (15.32%) had a good response, 7 worsened and 15 had a stabilized lung disease. Overall, 19 (73.07%)
patients had an improved or stabilized lung disease. After a 6-month follow-up, 12 (54.5%) of the 22 patients
showed an improved or stabilized lung disease.
Conclusions: Lung function was stabilized in a large proportion of patients unresponsive to cyclophosphamide
therapy and a beneficial outcome emerged from the analysis of HRCT lung scans. There was no significant
improvement of skin involvement, and the low dose was well tolerated. These data provide useful suggestions to
design future randomized clinical trials for SSc therapeutics.
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Systemic sclerosis (SSc; scleroderma) is a rare, multi-
system connective tissue disease characterized by wide-
spread microvascular lesions and increased deposition of
extracellular matrix components in the skin and internal
organs [1].
Systemic sclerosis interstitial lung disease (SSc-ILD)
and pulmonary arterial hypertension are a major cause
of scleroderma-related mortality, accounting for over
60% of all deaths [2]. Depending on the diagnostic
method used, interstitial lung disease is present in from
40 to 90% of SSc patients as bilateral basal alveolitis
evolving to diffuse fibrosis and restrictive respiratory
failure [3-6]. The pathogenesis of SSc-ILD is unknown
and is probably the result of a combination of inflam-
matory and immunologic mechanisms, which lead to de-
structive and fibrotic lesions. Available therapies for the
treatment of SSc-ILD are scarce and of limited benefit.
Imatinib mesylate (Gleevec; Novartis Europharm Ltd,
Wimblehurst Road, Horsham, West Sussex RH12 4AB,
UK) has been approved for the therapy of chronic mye-
logenous leukemia and gastrointestinal stromal tumors
[7]. Interest in use of imatinib mesylate in SSc lies in its
ability to interfere with the tyrosine kinases downstream of
the receptors for transforming growth factor beta and
platelet-derived growth factor, which are considered key
signaling molecules in the pathogenesis of SSc fibrosis [8,9].
Six clinical pilot trials in SSc patients have been pub-
lished, with a focus on the safety and effectiveness of
imatinib mesylate in the treatment of both cutaneous
and pulmonary involvement [10-15]. The results have
been controversial with regard to efficacy and all studies
were generally characterized by a poor tolerability.
In view of these discordant data, we designed a multi-
center, prospective, open-label trial with the following
characteristics: only SSc patients with active lung involve-
ment, despite previous therapy with cyclophosphamide,
were enrolled; a single dose of 200 mg/day imatinib mesy-
late was used; the study was structured according to
Simon’s optimal two-stage design [16,17]; and the goal
was to assess the effect on lung fibrosis and alveolitis, as
well as the tolerability of this regimen as a therapy for
SSc-ILD.
Methods
Study design
To evaluate the effect of the treatment with imatinib
mesylate on SSc-ILD, the study was structured according
to Simon’s optimal two-stage design [16], a strategy de-
vised for phase II studies to limit the number of subjects
who will undergo inefficacious therapy, consisting of
two subsequent enrolment phases [16,17]. Ten patients
(variable: n1) entered the first stage of the trial. En-
rolment would have been stopped and the drug rejectedif <10% of the patients (variable: P0) had met the pri-
mary end point at 6 months. Conversely, the study
would have been continued until 30 patients were en-
rolled in total (variable: n). The drug would have been
rejected in the case of a positive response rate in <30%
(variable: P1) of the patients completing the study.
The values of variables n1, n, P0, and P1 were set to
obtain a probability ≤0.05 of accepting a drug worse
than P0 after the first stage and a probability ≤0.2 of
rejecting a drug better than P1 at the end of the study.
Study population
From February 2009 to June 2011, 72 consecutive patients
with SSc and active pulmonary involvement that had
not improved after cyclophosphamide treatment were
screened for inclusion/exclusion criteria at 12 Italian cen-
ters. The reasons for exclusion were all registered. All SSc
patients fulfilled the American College of Rheumatology
preliminary criteria for the classification of SSc [18]. The
protocol, patient information sheet and consent form were
approved by the Ethics Committee of each participating
centre (see Acknowledgements for specific names of the
ethical bodies). The study was conducted in accordance
with the Declaration of Helsinki in its fifth edition (2000).
Written informed consent was obtained from all patients.
The diagnosis of active lung involvement required the
presence of grade 2 exertional dyspnea according to the
Mahler Baseline Dyspnea Index [19] plus interstitial alve-
olitis assessed by high-resolution computed tomography
(HRCT) scan (ground-glass opacifications involving at
least two lung segments) or neutrophilic (>3%) or eosino-
philic (>2%) alveolitis detected by bronchoalveolar lavage.
SSc patients were defined resistant to conventional im-
munosuppressive treatment if the forced vital capacity
(FVC) and/or diffusing lung capacity of carbon monoxide
(DLCO) had not increased by more than 15% after a cumu-
lative dosage of ≥6 g cyclophosphamide. SSc patients were
considered resistant to the treatment also in the event of a
partial pressure of oxygen in arterial blood decrease ≥15%
compared with baseline values. Evidence of active lung in-
volvement before cyclophosphamide therapy initiation
had to be documented.
Inclusion criteria were: SSc as defined above; presence
of active interstitial alveolitis; resistance to conventional
immunosuppressive treatment; age 18 to 80 years; ability
to give informed consent; and use of an acceptable
method of birth control (if applicable). Pregnancy had to
be ruled out before the beginning of the study.
Exclusion criteria were: severe pulmonary fibrosis, de-
fined as interstitial fibrosis (honeycombing pattern) invol-
ving ≥50% of the lung (assessed by HRCT scan); connective
tissue diseases other than SSc; smoking habit; pregnancy or
lactation; evidence of hepatic B virus or hepatic C virus
infection; severe anemia (hemoglobin ≤ 8 g/dl); hepatic
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fold above normal levels); moderate or severe renal failure
(creatinine clearance <59 ml/minute); severe heart failure
or ejection fraction ≤35% measured by echocardiography;
or evidence of thyroid disease.
Treatment
Eligible patients received oral imatinib mesylate (Gleevec;
Novartis Europharm Ltd) 200 mg (two tablets) once a day,
after breakfast, for 6 months. The drug was supplied every
3 months during the followup visits. The drug tablets were
counted and returned if they had not been used by pa-
tients for any reason. Immunosuppressive medications
were not allowed within 3 months prior to initiation of
imatinib. Cyclophosphamide had been stopped between 3
and 48 months (mean interval 14.96 months) before the
start of the study. A stable dose of oral prednisone
(≤15 mg/day) as well as calcium channel blockers or ilo-
prost were allowed. Every other symptomatic therapy was
permitted if not interfering with imatinib. Patients did not
receive immunosuppressive drugs in the 6 months follo-
wing treatment with imatinib.
Assessments
The study was open label for the patients and the physi-
cians directly involved in patient clinical evaluation.
Variables measured every 3 months included electrocar-
diography, routine blood and urine tests (urea, electro-
lytes, serum glucose, liver function tests urinalysis, resting
arterial blood gases, complete blood cell count, and
24-hour proteinuria), thyroid function tests, and creatine
kinase.
Pulmonary function tests and single-breath diffusing
capacity were performed in accordance with recom-
mended standards [20,21]. Physicians performing lung
function tests were not aware of being in an experimen-
tal setting and were blind to the treatment.
Results were expressed as liters (FVC) and ml/mmHg/
minute (DLco). Percentage variation between values re-
corded at baseline and 6 months was calculated as:
Δ ¼ T6=T0 100ð Þ–100
Pulmonary function tests and an HRCT scan were per-
formed at baseline, 6 months after the beginning of
treatment, and at 12 months (i.e. after a 6-month follow-
up) in the absence of clinical events that would interfere
with their interpretation.
Assessment of the HRCT scan pattern consisted of
sequential acquisition of 1 mm scans, spaced at 10 mm,
extending from the lung apices to below the costo-
phrenic angles. Images were reconstructed with a high
spatial frequency algorithm for lung analysis and were
viewed with lung window settings. Lung evaluation wasperformed at suspended end-inspiratory volume and
examination was carried out with patients in the prone
position to avoid lung opacities in the posterior lung. No
intravenous contrast material was used. Twenty broncho-
pulmonary segments were evaluated and a segment was
considered involved if ≥50% had a ground-glass appea-
rance [22].
HRCT scans were independently analyzed in a random
order by three radiologists who were not informed of
whether scans had been obtained before or after therapy.
Disagreements were resolved through collegial discus-
sion or by majority rule. Pulmonary function tests were
also evaluated blindly irrespective of the treatment.
The extent of skin involvement was assessed by
trained physicians using the modified Rodnan skin score
(mRSS), as described elsewhere [23]. Ad hoc training
was performed before the start of the study to limit
intra-observer and inter-observer variation less than 5%.
Outcomes
The first primary outcome was improvement of the pul-
monary involvement. Improvement was defined as an in-
crease of FVC >15% and/or increase of DLCO >15% and
partial pressure of oxygen in arterial blood >90% of initial
value and HRCT scan pattern defined as unchanged or
improved. HRCT was considered improved if there was
disappearance of ground-glass opacities in at least two
lung segments. The patient was considered worsened if
FVC or DLCO decreased >15% or if HRCT was worsened.
Change of FVC and DLCO between −15 and +15% with an
unchanged/improved HRCT was considered evidence of
stabilized disease. The second primary outcome was drug
tolerability.
Secondary outcomes were a reduction of skin thick-
ness evaluated by the mRSS and patient physical and
emotional wellness assessed by the Medical Outcomes
Short Form-36 score, Health Assessment Questionnaire,
and visual analogue scale for global wellness [24].
Study oversight
All consecutive SSc patients with active lung involve-
ment were screened by the participating centers for in-
clusion/exclusion criteria and identified with a PIN to
warrant privacy and anonymity.
A trained investigator from the Ancona Centre was
the internal quality controller of the study. All centers
were subject to direct and indirect controls (drugs’ ac-
countability, blinding procedures, control of case record
forms). After every quality control, an audit concerning
the wrong procedures was performed.
Adverse events were managed and classified as light,
moderate, and severe and as related, probably related,
and unrelated to the study drug, according to the com-
monly accepted guidelines [25].
Fraticelli et al. Arthritis Research & Therapy 2014, 16:R144 Page 4 of 10
http://arthritis-research.com/content/16/4/R144Statistical analysis
Since the data were not distributed normally, they were
expressed as median (25th to 75th percentile ranges) un-
less otherwise stated. Comparisons were made using the
nonparametric Wilcoxon test. Differences were con-
sidered statistically significant if P ≤ 0.05 (two-tailed).Results
The trial profile is outlined in Figure 1. Seventy-two
patients were screened, and 42 were excluded: 39 for not
satisfying inclusion criteria (Figure 1) and three for lack
of consent. Pretreatment demographic, clinical, and im-
munological features of the 30 enrolled patients are sum-
marized in Table 1. Median age was 51 (41.75 to 62) years
and median disease duration (defined as the time from the
onset of the first non-Raynaud’s phenomenon clinical
manifestation) was 3 years [1-6]. Nine patients (30%) were
male and 21 patients (70%) were female, all Caucasian.
Fourteen patients (46%) had limited cutaneous SSc and 16
patients (53.3%) had diffuse cutaneous SSc. The majority
of the patients (93.3%) were anti-topoisomerase-I-positive;
one patient was anti-centromere-positive and one patient
was Antinuclear antibodies-positive but lacked specific
SSc autoantibodies. In the whole group, median systolic
pulmonary artery pressure detected by echocardiography
was 30 (28.5 to 36.5) mmHg. After 12 months, 26 patients
completed the study, three patients died and one patient,
who did not complete the 6-month examination, was72 patients screened for 
eligibility 
1 pa
f
3 pati
1: PN
1 :su
1 : br
27 patients completed the 
study
42 pa
39 pa
3 refu
30 patients enrolled
26 patients analysed
Figure 1 Trial profile. Six-month data were obtained on all but four patie
patients. PNX, pneumothorax.excluded from the final analysis. The data therefore refer
to 26 patients.
Efficacy
After 6 months of treatment with imatinib, lung involve-
ment improved in four of 26 patients (15.32%), worsened
in seven patients (26.92%), and remained stable in 15 pa-
tients (57.69%). Nineteen (73.07%) patients thus had im-
proved or stabilized lung disease (Table 2).
Compared with baseline, three of the four patients clas-
sified as improved showed evidence of HRCT improve-
ment, while HRCT was unchanged in the remaining
patient (Table 2). In one out of the four patients with
interstitial lung disease improved by imatinib (Patient
509), the discrepancy between the improved DLco and the
worsened FVC is probably to be ascribed to chest wall re-
striction secondary to the increase of mRSS. In the sub-
group of 15 patients with stabilized disease, HRCT was
improved in nine patients and unchanged in six patients.
Interestingly, pulmonary functional tests lagged behind
improvement in HRCT in all patients.
Three of the seven patients who were classified as wor-
sened had an improved or unchanged HRCT (Table 2).
Figure 2A shows that after 6 months of treatment with
imatinib the median number of lung segments with
ground-glass opacities was significantly reduced com-
pared with baseline (5.5, 25th to 75th percentile ranges
4.0 to 9.50 vs. 10, 25th to 75th percentile ranges 6.0 to
13.75) (P = 0.0001). No difference was detected withtient lost at 
ollowup
ents died: 
X, 
dden death,
ain tumor
tients were excluded:
tients did not satisfy inclusion criteria; 
sed to participate.
nts. At 12-month visit, pulmonary function tests were available in 22
Table 1 Baseline demographic, clinical and
immunological features of the study population
Male/female 9 (30%)/21 (70%)
Age (years) 51 (41.75 to 62)
Disease duration (years) 3 (1 to 6)
Anti-DNA topoisomerase I/
anti-centromere antibodies
28 (93.3%)/1 (3.3%)
Systemic sclerosis, lcSSc/dcSSc 14 (46%)/16 (53.3%)
Pulmonary function tests
FVC% predicted 76.5 (63.23 to 89.30)
TLC% predicted 75 (65 to 86)
DLco% predicted 43 (37 to 54)
High-resolution computed tomography
Ground-glass 10 (6 to 13.75)
Honeycombing 10.5 (6.25 to 16.25)
Modified Rodnan skin score 10.5 (5.25 to 20)
Health Assessment Questionnaire 0.375 (0 to 1)
Data presented as number of patients (%) or median (25th to 75th percentile).
dcSSc, diffuse cutaneous systemic sclerosis; DLco, diffusion lung capacity of
carbon monoxide; FVC, forced vital capacity; lcSSc, limited cutaneous systemic
sclerosis; TLC, total lung capacity.
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bing (10.5, 25th to 75th percentile ranges 6.25 to 16.25
at T0; and 11, 25th to 75th percentile ranges 7.25 to
16.0 at T6) (P =NS) (Figure 2B). Patients classified as
improved or stabilized showed a relevant reduction in
the number of lung segments with ground-glass opaci-
ties (Figure 2C). This was statistically significant in the
subgroup of stable patients (P = 0.0002). In the improved
subgroup, the number of patients was too small for the
difference to be statistically significant.
In the subgroup of 19 patients with either improved or
stabilized lung disease, one patient had disappearance of
ground-glass opacities in two segments, and 11 patients
in more than two segments (Table 2).
At month 12, 6 months after the end of treatment, 12
of the 22 patients (54.5%) whose pulmonary function
tests were available for analysis had an improved or sta-
bilized disease compared with baseline (data not shown).
With regard to the secondary outcomes, no significant
improvement of the mRSS was noticed (data not shown).
Wellness, physical activities, and quality of life – assessed
by the visual analogue score, Health Assessment Ques-
tionnaire, and the Short Form-36 questionnaires respec-
tively – did not show any significant improvement except
for the emotional role of the Short Form-36 score (data
not shown).Adverse events
Serious adverse events requiring drug discontinuation
were registered in three cases (10%) (Table 3).One patient (Patient 178) died as a consequence of
pneumothorax occurring after central line positioning. The
patient was in poor clinical condition, and severely mal-
nourished due to malabsorption. Therapy with imatinib
was discontinued 5 days after the start. The adverse event
in this patient was judged to be not related to imatinib.
In a second patient (Patient 384) a neuroendocrine
tumor localized to the skull, meninges, and brain was
diagnosed 139 days after the start of imatinib. The pri-
mary tumor was ascribed to a pelvic mass with the same
histopathological features. Imatinib was discontinued
and chemotherapy and radiotherapy were initiated. The
patient died 44 days later. The tumor was probably
present at the time of enrolment and had not been de-
tected by the screening procedures. This adverse event
was judged as probably not related to imatinib.
Sudden death occurred in a third patient (Patient 663).
She was found dead in a primary care hospital where
she had been referred for weakness, lower limb edema,
and diarrhea, which had started a few days after colchi-
cine (1 mg/day) had been administered for condrocalci-
nosis. An autopsy was not performed. The patient had
been on imatinib for 11 days. The adverse event in this
patient was judged to be not related to imatinib.
A fourth patient (Patient 459) developed severe pneu-
monia requiring noninvasive ventilation 17 days after com-
pleting the 6-month therapy, The patient had advanced
lung fibrosis and a long history of steroid treatment. The
patient completely recovered. The adverse event in this pa-
tient was judged unlikely to be related to imatinib.
Overall adverse events were present in less than 20%
of the patients, mainly transient and well tolerated, with-
out subsequent withdrawal or dose adjustment of the ex-
perimental drug. The most common adverse events
were lower limb edema, cough, and infections (Table 4).
Discussion
Using strict enrolment and assessment criteria, only
15.3% of SSc patients with active interstitial lung disease
could be classified as improved after 6 months of treat-
ment with low-dose imatinib. This result fell short of the
30% rate target.
However, although the comparison is very problematic
for the reasons stated below, the results shown here are
encouraging when compared with those of Tashkin and
colleagues. Their study showed that improvement of
FVC between 10 and 15% was obtained in 5% and <5%
of SSc patients, respectively, after 12 months of oral
cyclophosphamide or placebo [26].
In the present study, the failure to meet the primary
end point could be ascribed to the clinical features of
the patients enrolled in this study, who had severe lung
disease as manifested by the lack of improvement after
intensive treatment with cyclophosphamide, and in some
Table 2 Pulmonary function tests and mRSS at baseline and 6 months, and HRCT outcome in 26 systemic sclerosis patients treated with imatinib
Patient
(PIN)
FVC
(l) T0
FVC
(l) T6
ΔFVC
(T0 – T6) (%)
DLco (ml/mmHg/
minute) T0
DLco (ml/mmHg/
minute) T6
ΔDLco
(T0 – T6) (%)
HRCTa
T0
HRCTa
T6
HRCT
(evaluation at T6)
mRSS
T0
mRSS
T6
ΔmRSS
(T0 – T6) (%)
Months from the end of CYC/
cumulative dose of CYC/
other therapies
86 3.23 3.84 −5.88 8.45 10.78 27.57 19/18 4/18 Improved 4 3 −25 21/10 g/Aza
509 3.36 2.71 –19.3 10.64 14.05 32.05 6/2 4/2 Improved 24 31 29.16 48/7.5 g/Mtx
642 1.53 1.57 2.61 8 10 25 9/9 6/9 Improved 5 6 20 11/70 g
649 1.79 1.83 2.23 8.44 9.54 19.62 6/8 7/9 Unchanged 3 3 0 3/10 g/CyA
18 2.35 2,31 –1.7 18.99 19.92 4.9 6/8 3/8 Improved 0 0 0 42/13.5 g/Aza
115 2.69 2.45 –8.92 16.1 17 6.83 4/2 4/2 Unchanged 20 20 0 12/18 g/Aza, Rtx
205 1.52 1.43 –5.92 4.9 5 2.04 6/20 0/20 Improved 5 6 29.16 22/21 g
214 3.16 3,16 0 12.9 14 8.53 10/8 1/9 Improved 29 25 −13.79 9/6 g
219 1.97 1.83 −7.1 8.5 8.1 −4,7 20/20 20/20 Unchanged 10 16 60 36/6 g/Aza
297 2,19 2.24 2.28 7.2 7.49 4.02 13/7 12/7 Unchanged 22 17 −22.72 20/6 g
304 2.41 2.56 6.22 15.1 14.4 −4.63 12/3 11/3 Unchanged 11 9 −18.18 3/6 g
371 3.14 3.56 13.37 17.8 19.7 10.67 6/8 0/8 Improved 6 6 0 4/8.2 g
432 1.77 1.82 2.82 5.31 5.77 8.66 14/17 13/17 Unchanged 9 9 0 8/9 g
482 1.55 1.43 −7.74 7.68 7.39 −3.78 11/14 1/14 Improved 5 4 −20 7/9 g
522 3.20 3.08 −3.75 13.18 13.2 0.15 12/6 4/5 Improved 28 31 10.71 10/9 g
586 2.21 2.42 9.5 8.6 9.1 5.81 6/12 5/12 Unchanged 28 30 7.14 3/6 g
696 3.29 3.27 −0.6 14.5 14.19 2.76 11/6 7/7 Improved 8 10 25 15/7,2 g
763 3.81 3.75 −1.5 16.4 16.9 3.05 14/13 8/13 Improved 17 20 17.64 15/6 g/Rtx
801 2.09 2.13 1.9 10.5 11.5 9.52 16/12 8/13 Improved 15 11 26.66 3/7,2 g
144 3.56 3.57 0.28 9.65 6.16 –36.16 9/14 4/16 Worsened 15 15 0 6/10 g
358 2.24 1.81 –19.2 8.30 7.6 –8.63 8/14 4/14 Improved 14 24 71.42 12/38 g/Aza
459 2.44 1.97 –19.26 10.4 9.9 –4.81 14/20 14/20 Unchanged 25 27 8 15/9 g
534 3.26 3.01 −7.6 15.12 14.93 −1.26 5/4 10/12 Worsened 0 0 0 28/10 g/Aza
552 1.95 1.95 0 8.98 7.86 −11.36 18/18 20/20 Worsened 28 31 10.71 8/20 g/Aza, MMF
706 1.86 1.7 −8.6 6.21 3.55 −42.83 6/20 6/20 Unchanged 10 10 0 7/6 g/Aza
789 2.04 2.12 3.9 10.7 10.4 −2.8 10/4 10/10 Worsened 7 10 42.85 21/7.2 g
Bold data indicate that patients responders: Roman data indicate that patients stabilized; italic data indicate that patients worsened. Aza, azathioprine; CyA, cyclosporine A; CYC, cyclophosphamide; DLco, diffusion lung
capacity of carbon monoxide; FVC, forced vital capacity; HRCT, high-resolution computed tomography; Mtx, methotrexate; MMF, mycofenomycophenolate mophetil; mRSS, modified Rodnan skin score; Rtx, rituximab;
T0, baseline; T6, 6-month visit; Δ = (Τ6/Τ0 × 100) – 100. aNumber of segments with ground-glass/honeycombing.
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Figure 2 Number of lung segments with high-resolution computed tomography ground-glass opacities and honeycombing in all
patients at baseline and at 6 months. Number of lung segments with high-resolution computed tomography ground-glass opacities (A) and
honeycombing (B) in all 26 patients at baseline and at 6 months (T6), and in the subgroups of patients classified as improved, stabilized, and worsened
after 6 months of treatment with imatinib (C). (A), (B) Data expressed as median with interquartile ranges. (C) Data expressed as absolute numbers of
lung segments.
Table 3 Serious adverse events
Patient PIN Event Duration of experimental therapy Attribution
178 Pneumothorax due to central line insertion. Death 5 days Not related
384 Malignancy. Death 139 days Probably not related
663 Sudden death 11 days Not related
459 Severe pneumonia with respiratory failure 6 months (17 days after the last dose of imatinib) Unlikely related
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Table 4 Adverse events in 26 systemic sclerosis patients
treated with imatinib
Adverse event Number of patients %
Lower limb edema 5 19.2
Cough 5 19.2
Infections 5 19.2
Urticaria/rash 4 15.3
Arthritis 2 7.6
Transient creatine kinase elevation 1 3.8
Diarrhea 1 3.8
Thrombophlebitis 1 3.8
Others 4 15.3
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to the target of ≥15% increase in pulmonary functional
tests (FVC and/or DLco) plus unchanged or improved
lung HRCT as evidence of a positive outcome. The cu-
mulative percentage of responder and stabilized patients
(73.07%) was high, but these data must be interpreted with
caution. First, a carryover effect of previous immunosup-
pressive therapy cannot be ruled out, although worsening
occurred in patients who had received an immuno-
suppressive therapeutic regimen like that of improved/
stabilized patients. Furthermore, it is worth noting that this
was an open trial without a control group representative of
the natural progression of the disease, and to our know-
ledge there are no data about the rate of progression of
lung alveolitis in patients who had failed cyclophosphamide
therapy.
Some patients with active SSc-ILD, however, may bene-
fit from imatinib treatment, especially those with HRCT
of the lung characterized by ground-glass (Figure 2). Iden-
tification of these patients is crucial, and in this respect it
is reasonable to suggest that: future trials with tyrosine
kinase inhibitors should include patients with less ad-
vanced lung disease – treating patients at an earlier stage
could be more rewarding, as suggested by the lack of
effect of imatinib on established fibrosis; longer treatment
should also be taken into consideration, since pulmonary
function tests lagged behind the improvement docu-
mented by HRTC; fixed doses of the drug have so far been
used in all clinical trials that have explored imatinib, but
alternative regimens with a tailored dose should be eva-
luated to maximize the benefit/adverse effects ratio; pa-
tients should be selected based on the level of activation
of platelet-derived growth factor receptors in lung tissue
[27]; and other tyrosine kinase inhibitors may have more
efficacious therapeutic effects.
Not significant improvement was seen in the extent of
skin fibrosis, probably as a result of enrolment of pa-
tients with minimal skin involvement.The main difference between this and previous imatinib
trials is the lower dose employed and the enrollment of
patients who had failed immunosuppressive therapy. In
their pilot study, Khanna and colleagues found a statisti-
cally nonsignificant improvement in the predicted FVC%,
and radiological findings were not included in their evalu-
ation. Eight out of 20 SSc patients who received up to
600 mg imatinib/day did not complete the study either be-
cause of adverse events (seven patients) or because they
were lost to follow-up (one patient) [12]. While the study
of Pope and colleagues was stopped early because of poor
tolerability of imatinib (200 mg twice a day) [10],
the open-label single-arm clinical trial of Spiera and col-
leagues demonstrated improvement of mRSS after admin-
istration of imatinib 400 mg daily [11]. Twenty-four of 30
patients completed 12 months of therapy and their pre-
dicted FVC improved by 6.4% (P = 0.008). No data regar-
ding HRCT were provided. In the study by Distler and
colleagues, imatinib (up to 600 mg daily) had no sig-
nificant effect on mRSS in a group of patients with early
diffuse SSc [13]. Treatment was characterized by poor
tolerability and adverse events. Finally, no efficacy on
mRSS was demonstrated by Prey and colleagues in a ran-
domized double-blinded controlled study using 400 mg
daily in a mixed population of patients with morphea and
SSc patients with extensive skin involvement [15].
This trial raises some speculation about the mechanisms
of action of imatinib. The disappearance of ground-glass
opacities implies an immunomodulatory mechanism,
which is probably based on the competitive inhibition of
distinct tyrosine kinases by imatinib. Besides platelet-
derived growth factor receptor α/β, the nonreceptor Abelson
tyrosine kinase (c-abl) [28], stem cell factor receptor
c-KIT [28], macrophage colony-stimulating factor recep-
tor (c-fms) [29] and lymphocyte-associated kinase (lck)
[30] – which are all involved in development, activation,
proliferation and function of immune cells – are inhibited
by imatinib. In this respect, imatinib has been investigated
in several models of kidney disease [31] and shown to
ameliorate immunologic and fibrotic features. Further-
more, imatinib 100 mg/kg suppressed the progression and
attenuated the severity of established experimental en-
cephalomyelitis, a mouse model of multiple sclerosis [32],
of autoimmune arthritis [33], and of autoimmune diabetes
in mice [34]. One can thus speculate that inhibition of im-
mune response may contribute to halting the progression
of the fibrotic mechanisms regardless of the pathogenesis.
The low dose used was probably responsible for the
negligible side effects observed in this study. This differs
remarkably from the results of the other published trials,
which were characterized by the poor tolerability of the
treatment due to the higher doses employed [10-13].
With regard to the adverse events in our study, we ex-
perienced three deaths and one serious adverse event.
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form of disease. One patient had fatal complications
after wrong positioning of a central line. A second pa-
tient was diagnosed with a neuroendocrine tumor lo-
calized to the skull, meninges, and brain after starting
the experimental drug. In this case, imatinib was stopped
immediately but despite prompt chemotherapy and ra-
diotherapy the patient died after few weeks. The third
patient, who was taking colchicine for condrocalcinosis,
suffered a sudden death in a primary care hospital where
she was referred for weakness, lower limb edema, and
diarrhea. Unfortunately an autopsy was not performed.
The last patient developed severe pneumonia requiring
noninvasive ventilation but she had advanced fibrosis
and had completed the therapy 17 days earlier. We think
that two deaths are not related to the treatment and the
third is unlikely to be related, and all were as a conse-
quence of the severity of the disease.
Conclusions
Low-dose imatinib stabilized pulmonary involvement in
scleroderma patients who had not previously responded
to cyclophosphamide. Side effects were negligible and
the dosage employed was well tolerated. Together with
most recently published pilot studies, these data make
this drug attractive for future randomized clinical trials.
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